Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cytek Biosciences, Inc.CTKB · Entity 5345 | Director · PRESIDENT AND CEO | August 18, 2026 | August 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cytek Biosciences, Inc.
Report date August 18, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,561,029 |
Ending reported balance
After 2026-08-18 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2026-08-18 · Exercise / conversion · Acquired 11,781 · Balance 5,488,984 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 2 · 2026-08-18 · Tax withholding · Disposed 2,869 · Balance 5,486,115 F2: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Row 3 · 2026-08-18 · Exercise / conversion · Acquired 22,100 · Balance 5,508,215 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 4 · 2026-08-18 · Tax withholding · Disposed 5,382 · Balance 5,502,833 F2: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Row 5 · 2026-08-18 · Exercise / conversion · Acquired 29,002 · Balance 5,531,835 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 6 · 2026-08-18 · Tax withholding · Disposed 7,062 · Balance 5,524,773 F2: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Row 7 · 2026-08-18 · Exercise / conversion · Acquired 57,212 · Balance 5,581,985 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 8 · 2026-08-18 · Tax withholding · Disposed 20,956 · Balance 5,561,029 F2: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 27,494 |
Reported balance
After 2026-08-18 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-18 · Exercise / conversion · Disposed 11,781 · Balance 27,494 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 139,973 |
Reported balance
After 2026-08-18 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-08-18 · Exercise / conversion · Disposed 22,100 · Balance 139,973 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 299,694 |
Reported balance
After 2026-08-18 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-08-18 · Exercise / conversion · Disposed 29,002 · Balance 299,694 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 820,054 |
Reported balance
After 2026-08-18 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-08-18 · Exercise / conversion · Disposed 57,212 · Balance 820,054 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F6: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2026 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
F2: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.
F3: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter.
F4: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter.
F5: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter.
F6: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2026 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2023 Filed Mar 8, 2023 00:48 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantEmployee Stock Option (Right to Buy) · Derivative | 284,900 | $0.00 Strike: $10.61 | $0.00 |
DisclosureSEC source: 0001209191-23-016979 · doc4.xml · derivative · entry 2 Jiang Wenbin · CIK 0001872873 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,900 Underlying: Common Stock · 284,900 shares Expires 2033-03-03 F3 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over four years from the vesting commencement date of March 3, 2023. The option becomes fully vested on March 3, 2027. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:43 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 6,758 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-012356 · doc4.xml · derivative · entry 3 Jiang Wenbin · CIK 0001872873 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,852 Underlying: Common Stock · 6,758 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:43 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 2,633 | $10.97 | $28,884.01 |
DisclosureSEC source: 0001209191-23-012356 · doc4.xml · nonDerivative · entry 2 Jiang Wenbin · CIK 0001872873 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,724,439 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on February 21, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:43 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 6,758 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-012356 · doc4.xml · nonDerivative · entry 1 Jiang Wenbin · CIK 0001872873 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,727,072 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 00:26 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $13.19 | $263,800.00 |
DisclosureSEC source: 0001209191-23-007911 · doc4.xml · nonDerivative · entry 1 Jiang Wenbin · CIK 0001872873 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,720,314 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.93 to $13.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 09, 2023 Filed Jan 10, 2023 23:26 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $10.66 | $213,200.00 |
DisclosureSEC source: 0001209191-23-002859 · doc4.xml · nonDerivative · entry 1 Jiang Wenbin · CIK 0001872873 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,740,314 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.47 to $10.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 22:57 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $11.86 | $237,200.00 |
DisclosureSEC source: 0001209191-22-060573 · doc4.xml · nonDerivative · entry 2 Jiang Wenbin · CIK 0001872873 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,760,314 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.73 to $12.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 29, 2022 Filed Dec 9, 2022 22:57 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-060573 · doc4.xml · nonDerivative · entry 1 Jiang Wenbin · CIK 0001872873 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,780,314 Read SEC document |
| November 18, 2022 Filed Nov 22, 2022 23:18 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 6,758 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-058475 · doc4.xml · derivative · entry 3 Jiang Wenbin · CIK 0001872873 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,610 Underlying: Common Stock · 6,758 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| November 18, 2022 Filed Nov 22, 2022 23:18 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 2,264 | $14.75 | $33,394.00 |
DisclosureSEC source: 0001209191-22-058475 · doc4.xml · nonDerivative · entry 2 Jiang Wenbin · CIK 0001872873 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,790,314 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| November 18, 2022 Filed Nov 22, 2022 23:18 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 6,758 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-058475 · doc4.xml · nonDerivative · entry 1 Jiang Wenbin · CIK 0001872873 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,792,578 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 07, 2022 Filed Nov 8, 2022 22:44 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $14.76 | $295,200.00 |
DisclosureSEC source: 0001209191-22-056149 · doc4.xml · nonDerivative · entry 1 Jiang Wenbin · CIK 0001872873 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,785,820 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.59 to $14.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 07, 2022 Filed Oct 11, 2022 21:42 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $14.79 | $295,800.00 |
DisclosureSEC source: 0001209191-22-053368 · doc4.xml · nonDerivative · entry 1 Jiang Wenbin · CIK 0001872873 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,805,820 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.49 to $15.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 07, 2022 Filed Sep 10, 2022 00:06 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $12.89 | $257,800.00 |
DisclosureSEC source: 0001209191-22-049368 · doc4.xml · nonDerivative · entry 1 Jiang Wenbin · CIK 0001872873 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,825,820 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.27 to $13.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 18, 2022 Filed Aug 19, 2022 23:37 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 6,758 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-046947 · doc4.xml · derivative · entry 3 Jiang Wenbin · CIK 0001872873 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,368 Underlying: Common Stock · 6,758 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| August 18, 2022 Filed Aug 19, 2022 23:37 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 2,479 | $14.06 | $34,854.74 |
DisclosureSEC source: 0001209191-22-046947 · doc4.xml · nonDerivative · entry 2 Jiang Wenbin · CIK 0001872873 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,845,820 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 18, 2022 Filed Aug 19, 2022 23:37 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 6,758 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-046947 · doc4.xml · nonDerivative · entry 1 Jiang Wenbin · CIK 0001872873 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,848,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 21:59 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $15.09 | $301,800.00 |
DisclosureSEC source: 0001209191-22-045286 · doc4.xml · nonDerivative · entry 1 Jiang Wenbin · CIK 0001872873 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,841,541 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.59 to $15.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 07, 2022 Filed Jul 8, 2022 21:59 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $11.19 | $223,800.00 |
DisclosureSEC source: 0001209191-22-041705 · doc4.xml · nonDerivative · entry 1 Jiang Wenbin · CIK 0001872873 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,861,541 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.02 to $11.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 07, 2022 Filed Jun 10, 2022 00:08 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $10.75 | $215,000.00 |
DisclosureSEC source: 0001209191-22-035656 · doc4.xml · nonDerivative · entry 1 Jiang Wenbin · CIK 0001872873 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,881,541 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.50 to $10.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 18, 2022 Filed May 20, 2022 23:15 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 9,011 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-031168 · doc4.xml · derivative · entry 3 Jiang Wenbin · CIK 0001872873 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,126 Underlying: Common Stock · 9,011 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| May 18, 2022 Filed May 20, 2022 23:15 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon STock | 3,510 | $9.65 | $33,871.50 |
DisclosureSEC source: 0001209191-22-031168 · doc4.xml · nonDerivative · entry 2 Jiang Wenbin · CIK 0001872873 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,901,541 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 18, 2022 Filed May 20, 2022 23:15 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 9,011 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-031168 · doc4.xml · nonDerivative · entry 1 Jiang Wenbin · CIK 0001872873 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,905,051 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 09, 2022 Filed May 12, 2022 13:18 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $8.01 | $160,200.00 |
DisclosureSEC source: 0001209191-22-028461 · doc4.xml · nonDerivative · entry 1 Jiang Wenbin · CIK 0001872873 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,896,040 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.77 to $8.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 07, 2022 Filed Apr 8, 2022 21:33 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $10.54 | $210,800.00 |
DisclosureSEC source: 0001209191-22-023887 · doc4.xml · nonDerivative · entry 1 Jiang Wenbin · CIK 0001872873 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,916,040 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.36 to $10.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 22:55 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 1,200 | $13.79 | $16,548.00 |
DisclosureSEC source: 0001209191-22-017212 · doc4.xml · nonDerivative · entry 3 Jiang Wenbin · CIK 0001872873 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,936,040 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.66 to $13.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 22:55 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 18,800 | $12.58 | $236,504.00 |
DisclosureSEC source: 0001209191-22-017212 · doc4.xml · nonDerivative · entry 2 Jiang Wenbin · CIK 0001872873 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,937,240 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.28 to $13.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 22:55 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionStock Option (Right to Buy) · Derivative | 66,665 | $0.00 Strike: $0.25 | $0.00 |
DisclosureSEC source: 0001209191-22-017212 · doc4.xml · derivative · entry 4 Jiang Wenbin · CIK 0001872873 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,665 shares Expires 2022-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 22:55 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 66,665 | $0.25 | $16,666.25 |
DisclosureSEC source: 0001209191-22-017212 · doc4.xml · nonDerivative · entry 1 Jiang Wenbin · CIK 0001872873 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,956,040 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 22:57 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantRestricted Stock Units · Derivative | 108,137 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015002 · doc4.xml · derivative · entry 2 Jiang Wenbin · CIK 0001872873 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,137 Underlying: Common Stock · 108,137 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 22:57 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantStock Option (Right to Buy) · Derivative | 163,158 | $0.00 Strike: $13.64 | $0.00 |
DisclosureSEC source: 0001209191-22-015002 · doc4.xml · derivative · entry 1 Jiang Wenbin · CIK 0001872873 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,158 Underlying: Common Stock · 163,158 shares Expires 2032-02-28 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly over four years from the vesting commencement date of January 1, 2022. The option becomes fully vested on January 1, 2026. Read SEC document |
| February 07, 2022 Filed Feb 9, 2022 22:52 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $14.40 | $288,000.00 |
DisclosureSEC source: 0001209191-22-008158 · doc4.xml · nonDerivative · entry 2 Jiang Wenbin · CIK 0001872873 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,889,375 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.01 to $14.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 66,665 shares received as a liquidation distribution from WYTJ LLC. In prior reports, the Reporting Person reported beneficial ownership of 2,666,600 shares of the Issuer's common stock held by WYTJ LLC. Read SEC document |
| December 04, 2021 Filed Feb 9, 2022 22:52 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-008158 · doc4.xml · nonDerivative · entry 1 Jiang Wenbin · CIK 0001872873 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,842,710 Read SEC document |
| July 22, 2021 Filed Jul 27, 2021 01:46 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-048266 · doc4.xml · derivative · entry 1 Jiang Wenbin · CIK 0001872873 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2031-07-22 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 25% of the shares subject to the option vests on July 22, 2022; and 1/48th of the shares subject to the option vest monthly thereafter over the following three years. Read SEC document |
| July 22, 2021 Filed Jul 28, 2021 00:55 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | ConversionSeries A Preferred Stock · Derivative | 2,666,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-048384 · doc4.xml · derivative · entry 2 Jiang Wenbin · CIK 0001872873 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 2,666,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock automatically converted on a one-for-one basis into Common Stock upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock automatically converted on a one-for-one basis into Common Stock upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock automatically converted on a one-for-one basis into Common Stock upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F2 · ownership.nature: These securities are held by WYTJ LLC for which the Reporting Person is a Manager. The Reporting Person disclaims beneficial ownership of the shares held by WYTJ LLC except to the extent of his pecuniary interest therein, if any. Read SEC document |
| July 22, 2021 Filed Jul 28, 2021 00:55 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | ConversionCommon Stock | 2,666,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-048384 · doc4.xml · nonDerivative · entry 1 Jiang Wenbin · CIK 0001872873 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,666,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Preferred Stock automatically converted on a one-for-one basis into Common Stock upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F2 · balance_after: These securities are held by WYTJ LLC for which the Reporting Person is a Manager. The Reporting Person disclaims beneficial ownership of the shares held by WYTJ LLC except to the extent of his pecuniary interest therein, if any. F2 · ownership.nature: These securities are held by WYTJ LLC for which the Reporting Person is a Manager. The Reporting Person disclaims beneficial ownership of the shares held by WYTJ LLC except to the extent of his pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.